NEW YORK, September 28, 2022
Dieta Health's CEO, Asaf Kraus, had the exciting opportunity to present our cutting-edge technology and vision for the future of gastrointestinal (GI) care at Pfizer's headquarters in New York City. This presentation comes after Pfizer's recent acquisition of Arena Pharmaceuticals, a GI-focused pharmaceutical company. Last year, Dieta Health secured second place in Arena's innovation challenge, further highlighting the potential impact of our technology on the GI field.
The event showcased the remarkable potential at the intersection of digital health, artificial intelligence (AI), and the pharmaceutical industry. Dieta Health's AI-driven stool image recognition technology has already demonstrated several significant use cases, promising to revolutionize the way digestive outcomes are measured and monitored.
Asaf's presentation emphasized the value of Dieta Health's technology in providing more accurate diagnoses and improving patient care. By working closely with pharmaceutical industry leaders like Pfizer, Dieta Health aims to advance the field of gastroenterology and contribute to the development of innovative treatments for GI disorders.
